How to buy Inhibrx stock | $38.14

Inhibrx Inc is a biotechnology business based in the US. Inhibrx shares (INBX) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibrx employs 84 staff and has a trailing 12-month revenue of around 0.00.

Inhibrx stock price (NASDAQ: INBX)

Use our graph to track the performance of INBX stocks over time.

Inhibrx shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$38.14
52-week range	$14.27 - $50.97
50-day moving average	$33.47
200-day moving average	$26.15
Wall St. target price	$47.60
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.23

Buy Inhibrx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Inhibrx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inhibrx price performance over time

Historical closes compared with the close of $38.14 from 2021-10-22

1 week (2021-10-15)	-3.95%
1 month (2021-09-24)	3.73%
3 months (2021-07-23)	31.52%
6 months (2021-04-23)	100.95%

1 year (2020-10-23)	99.27%
2 years (2019-10-20)	N/A
3 years (2018-10-20)	N/A
5 years (2016-10-20)	N/A

Inhibrx financials

Revenue TTM	$10.5 million
Gross profit TTM	$-60,607,000
Return on assets TTM	-54.4%
Return on equity TTM	-567.79%
Profit margin	0%
Book value	$1.17
Market capitalisation	$1.5 billion

TTM: trailing 12 months

Shorting Inhibrx shares

There are currently 856,535 Inhibrx shares held short by investors – that's known as Inhibrx's "short interest". This figure is 17.6% up from 728,424 last month.

There are a few different ways that this level of interest in shorting Inhibrx shares can be evaluated.

Inhibrx's "short interest ratio" (SIR)

Inhibrx's "short interest ratio" (SIR) is the quantity of Inhibrx shares currently shorted divided by the average quantity of Inhibrx shares traded daily (recently around 147170.96219931). Inhibrx's SIR currently stands at 5.82. In other words for every 100,000 Inhibrx shares traded daily on the market, roughly 5820 shares are currently held short.

However Inhibrx's short interest can also be evaluated against the total number of Inhibrx shares, or, against the total number of tradable Inhibrx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inhibrx's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Inhibrx shares in existence, roughly 20 shares are currently held short) or 0.0491% of the tradable shares (for every 100,000 tradable Inhibrx shares, roughly 49 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inhibrx.

Find out more about how you can short Inhibrx stock.

Inhibrx share dividends

We're not expecting Inhibrx to pay a dividend over the next 12 months.

Inhibrx overview

Inhibrx, Inc. , a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency. Its preclinical programs include INBRX-106, a single domain antibody based hexavalent agonist of OX40 for a range of oncology indications. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California.

Frequently asked questions

What percentage of Inhibrx is owned by insiders or institutions?
Currently 39.979% of Inhibrx shares are held by insiders and 55.38% by institutions. How many people work for Inhibrx?
Latest data suggests 84 work at Inhibrx. When does the fiscal year end for Inhibrx?
Inhibrx's fiscal year ends in December. Where is Inhibrx based?
Inhibrx's address is: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037 What is Inhibrx's ISIN number?
Inhibrx's international securities identification number is: US45720L1070